These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7703204)

  • 1. Is leprosy blindness avoidable? The effect of disease type, duration, and treatment on eye damage from leprosy in Uganda.
    Waddell KM; Saunderson PR
    Br J Ophthalmol; 1995 Mar; 79(3):250-6. PubMed ID: 7703204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 22nd Kellersberger Memorial Lecture, 1997. Preventing loss of sight from leprosy.
    Waddell KM
    Ethiop Med J; 1997 Oct; 35(4):263-70. PubMed ID: 10214441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular manifestation in treated multibacillary Hansen's disease.
    Parikh R; Thomas S; Muliyil J; Parikh S; Thomas R
    Ophthalmology; 2009 Nov; 116(11):2051-7.e1. PubMed ID: 19766316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy.
    Daniel E; Ffytche TJ; Kempen JH; Rao PS; Diener-West M; Courtright P
    Br J Ophthalmol; 2006 Aug; 90(8):949-54. PubMed ID: 16707521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug therapy and eye disease in leprosy: a cross-sectional study in the People's Republic of China.
    Courtright P; Hu LF; Li HY; Lewallen S
    Int J Epidemiol; 1994 Aug; 23(4):835-42. PubMed ID: 8002199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of ocular morbidity and blindness in leprosy--a three centre study in Eastern India.
    Thompson KJ; Allardice GM; Babu GR; Roberts H; Kerketta W; Kerketta A
    Lepr Rev; 2006 Jun; 77(2):130-40. PubMed ID: 16895069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of blindness in leprosy and the role of the Vision 2020 Programme.
    Hogeweg M; Keunen JE
    Eye (Lond); 2005 Oct; 19(10):1099-105. PubMed ID: 16304590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002).
    Pandey A; Uddin MJ; Patel R
    Lepr Rev; 2005 Jun; 76(2):112-8. PubMed ID: 16038244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
    Rao PN; Suneetha S; Pratap DV
    Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lagophthalmos in a multibacillary population under multidrug therapy in the People's Republic of China.
    Courtright P; Lewallen S; Li HY; Hu LF; Yang JW
    Lepr Rev; 1995 Sep; 66(3):214-9. PubMed ID: 7500816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iris atrophy in patients with newly diagnosed multibacillary leprosy: at diagnosis, during and after completion of multidrug treatment.
    Daniel E; Sundar Rao PS; Ffytche TJ; Chacko S; Prasanth HR; Courtright P
    Br J Ophthalmol; 2007 Aug; 91(8):1019-22. PubMed ID: 17108015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nerve function impairment in leprosy at diagnosis and at completion of MDT: a retrospective cohort study of 786 patients in Bangladesh.
    Richardus JH; Finlay KM; Croft RP; Smith WC
    Lepr Rev; 1996 Dec; 67(4):297-305. PubMed ID: 9033200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of ocular morbidity among multibacillary leprosy patients during a 2 year course of multidrug therapy.
    Daniel E; Ffytche TJ; Sundar Rao PS; Kempen JH; Diener-West M; Courtright P
    Br J Ophthalmol; 2006 May; 90(5):568-73. PubMed ID: 16622085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual sight-threatening lesions in leprosy patients completing multidrug therapy and sulphone monotherapy.
    Ffytche TJ
    Lepr Rev; 1991 Mar; 62(1):35-43. PubMed ID: 2034023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular findings in leprosy patients in Nepal in the era of multidrug therapy.
    Nepal BP; Shrestha UD
    Am J Ophthalmol; 2004 May; 137(5):888-92. PubMed ID: 15126154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with sight threatening lesions of leprosy in patients on multidrug therapy.
    Rohatgi J; Dhaliwal U; Singal A
    J Indian Med Assoc; 2004 Jun; 102(6):297-8, 300, 302-3. PubMed ID: 15636037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of eye disease in "cured" leprosy patients: implications for understanding the pathophysiology of ocular disease and for addressing eyecare needs.
    Lewallen S; Tungpakorn NC; Kim SH; Courtright P
    Br J Ophthalmol; 2000 Aug; 84(8):817-21. PubMed ID: 10906083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study on the impact of FD-MDT on 200 leprosy patients.
    Vara N; Marfatiya Y
    Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of ocular complications in leprosy patients seen in the United Kingdom over a period of 21 years.
    Malik AN; Morris RW; Ffytche TJ
    Eye (Lond); 2011 Jun; 25(6):740-5. PubMed ID: 21423140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leprosy--a new look at an old disease.
    Whitcher JP; Srinivasan M
    Br J Ophthalmol; 2000 Aug; 84(8):809-10. PubMed ID: 10906079
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.